Medical Necessity Addendum (IMRT)

Patient: [Full name]    MRN: [MRN]    DOB: [DOB]    Date of Service: [Date]    Facility: [Facility name]

Treating Radiation Oncologist: [Physician name, credentials]

Diagnosis/Treatment Site: [Primary cancer/site], [Laterality if applicable], [Key involved regions/nodal levels]

Associated Treatment Plan: [Plan name or ID]; [Approval date / Plan pending final approval]

Clinical Context

(Provide a concise, patient-specific summary using a short paragraph or 3–5 bullets. Include only items directly relevant to IMRT/VMAT selection.)

• [Cancer diagnosis and histology]; [Clinical or pathologic stage] (Use "Staging pending" if not yet finalized.)
• [Treatment intent: curative / definitive / adjuvant / salvage / palliative]
• [Prior therapies affecting planning: surgery / systemic therapy / prior RT] (Include only if they influence target/OAR constraints.)
• [Patient-specific toxicity risk factors] (Include only if they directly affect OAR constraints or technique selection, e.g., baseline organ dysfunction, connective tissue disease.)

Requested Modality and Technical Approach

• Requested modality: [IMRT / VMAT]
• Treatment volume(s): [Target volumes covered by this request]
• Simulation and image fusion: [CT simulation date]; [MRI / PET fusion if used for target delineation]
• Immobilization: [Immobilization device(s)]
• Motion management: [4DCT / breath-hold / respiratory gating / abdominal compression / not applicable] (Include only for thoracic, hepatic, pancreatic, or upper abdominal sites where motion impacts dose gradients.)
• Physics QA: [Reference to QA documentation location]

Medical Necessity for IMRT

IMRT/VMAT is medically necessary for this patient to adequately treat [target volume(s)] while meeting dose constraints for [key OARs] given [patient-specific anatomic/clinical reason].

(Include 2–4 of the following rationales that apply to this patient. Each must reference specific anatomy or constraints—generic "standard of care" language is insufficient.)

• [Target geometry/complexity, e.g., concave or irregular target wrapping around named OAR(s)]
• [Proximity or overlap of target with critical structures requiring steep dose gradients]
• [Simultaneous integrated boost or dose painting with specified dose levels]
• [Re-irradiation with cumulative OAR tolerance limiting incremental dose]
• [Dose-escalation requirement that cannot be achieved safely with 3DCRT]

OARs and Dose Constraints

(List only binding constraints that drive IMRT selection. Include structures within or near high-dose regions. Do not infer numeric values not sourced from the actual plan.)

• [OAR name]: [Constraint metric] ≤ [Limit value with units] (Clinical rationale if non-standard, e.g., solitary organ, prior surgery)
• [OAR name]: [Constraint metric] ≤ [Limit value with units]
• [OAR name]: [Constraint metric] ≤ [Limit value with units]

Why 3DCRT Is Insufficient

(Select one pathway; omit the other.)

Path A – Comparative planning evidence: (Use if a 3D plan or feasibility assessment was performed.)

• [3DCRT approach evaluated]
• [Specific OAR constraint exceeded]: [OAR and metric] = [Observed value] exceeded [Limit]; or [Target coverage compromise required]: [Description of undercoverage] to meet [OAR] constraint
• [Comparative result]: IMRT/VMAT achieves acceptable target coverage while meeting [named OAR] constraints.

Path B – Anatomy-based rationale: (Use if no comparison plan was performed.)

• [Anatomic constraint, e.g., concave target around OAR, overlapping dose levels requiring inverse planning]
• [Explicit unacceptable tradeoff]: 3DCRT would require either undercoverage of [target volume] or exceedance of [specific OAR] tolerance.

Re-Irradiation Considerations

(Include only if prior radiation overlaps the current treatment region. Omit this section entirely otherwise.)

• Prior RT: [Site and approximate dates]; [Dose/fractionation if known, otherwise "Unknown - records unavailable"]
• Limiting OAR(s): [Structures requiring minimized incremental dose due to cumulative tolerance]
• Composite dose assessment: [Performed / Not performed]; [Location of composite documentation if applicable]
• Records obtained: [Summary of prior RT records obtained or attempts made if incomplete]

Supporting Documentation

The physician reviewed simulation imaging, target and OAR contours, representative isodose distributions, and DVH summaries for targets and OARs. [DVH summary pages / isodose screenshots attached / available at: location reference]. Physics QA documentation maintained in [departmental QA system/location].

Conclusion and Attestation

Based on this patient's anatomy and required target coverage while meeting the OAR constraints documented above, IMRT/VMAT is medically necessary. Conventional or 3D conformal techniques would not achieve clinically acceptable target coverage without exceeding specified OAR tolerances.

Radiation Oncologist Signature: _____________________    Date/Time: [Date/time]